

University of California at Los Angeles – School of medicine

Curriculum Vitae

Date: July, 2009

Pinchas Cohen

Professor and Chief, Pediatric Endocrinology, UCLA

Home Address: 16577 Chattanooga Place, Pacific Palisades CA 90272-2332 Tel: 310-230-3119

Office Address: Division of Endocrinology and Diabetes, Department of Pediatrics
Mattel Children's Hospital at the
University of California, Los Angeles
David Geffen School of Medicine at UCLA
MDCC 22-315, 10833 Le Conte Avenue
Los Angeles CA 90095-1752
Tel: 310-206-5844, Fax: 310-206-5843
E-MAIL: hassy@mednet.ucla.edu

Birth: June 14th, 1957 Kfar Saba, Israel.

Citizenship: US citizen (1998). Social Security Number available upon request.

Family: Married: Wing-Sze Cheung. Children: Ilana (1999) & Gidon (2001)

Military Service: 1975-1978 Israeli Air Force and Medical Corps

Education: 1978-1986 M.D., (with highest honors)
Faculty of Medicine, Technion, Haifa, Israel

Postgraduate Training and Fellowship Appointments:

1984-1986 Research Associate in Endocrinology and Diabetes
Faculty of Medicine, Technion, Haifa, Israel

1986-1989 Intern and Resident, Department of Pediatrics,
Stanford University, Stanford, California

1989-1992 Pediatric Endocrine/Diabetes Fellow,
Department of Pediatrics, Stanford, California

Faculty Appointments:

- 1992 Assistant Professor, Department of Pediatrics,
University of Pennsylvania, School of Medicine
Philadelphia, Pennsylvania
- 1997 Associate Professor (*with tenure*), Department of Pediatrics,
University of Pennsylvania, School of Medicine
- 1999 Professor of Pediatrics,
University of California at Los Angeles, School of Medicine

Administrative Appointments:

- 1996-9 Program Director, Pediatric Endocrinology and Diabetes
University of Pennsylvania
- 1998-9 Associate Chief, Division of Endocrinology/Diabetes,
Children's Hospital of Philadelphia, Philadelphia, PA.
- 1999- Director of Endocrine/Diabetes Research and Training
Department of Pediatrics, UCLA.
- 2000-4 Site Director, Glaser Clinical Research Network
- 2001- Chief, Division of Endocrinology and Diabetes
Department of Pediatrics, UCLA.
- 2003- Director, Pilot and Feasibility Core
UCLA/UCSD Diabetes Endocrinology Research Center
- 2007- Associate Director, UCSD/UCLA DERC

Specialty Certification:

- 1993 Diplomat, American Board of Pediatrics (recertified)
- 1995 Diplomat, American Board of Pediatric Endocrinology (recertified)

Licensure:

California and Pennsylvania

Awards, Honors and Membership in Honorary Societies:

1982	The David and Margaret Rue Award for Outstanding Student
1984	The Israeli Diabetes Foundation Young Investigator of the Year
1985	First prize for MD thesis
1986	Graduated from Medical School with highest honors
1989	Juvenile Diabetes Foundation Fellow
1990	Lawson Wilkins Society Research Fellow (Lilly Award)
1991	WSPR-David W. Smith Pediatric Trainee Award (Ross Award)
1992	Child Health Research Center Investigator
1993	American Diabetes Association Career Development Award
1995	Elected member: Society for Pediatric Research
1996	Voted into "The Best Doctors in America"
1997	Masters of Science (Honorary), University of Pennsylvania
1998	Honorary Member: Japanese Society of Pediatric Endocrinology
1999-	CaP Cure Research Award
2000	Pfeiffer Foundation Research Award
2006	Elected member: American Pediatric Society (APS)
2007	APS Outstanding Science Award
2009	Stanford University Kroc visiting Professorship
2009	Awarded the NIH-Director Transformative RO1

National Advisory Service:

1996-9	Member, Board of Directors Philadelphia Endocrine Society
1997-2001	Board Member: Association of Program Directors in Endocrinology
1997-	Executive Board Member of the International IGF Society
1997-2001	Member LW PES Program Directors Committee
1998-	Executive Council Member: Growth Hormone Research Society
1999-	Member: Advisory Board for the University of Washington Cancer Program
2002-2005	Member: Endocrine Society Steering Committee
2002-2006	Member LW PES Drugs and Therapeutics Committee
2004-	Member: Advisory Board for the European Precocious Puberty Consortium
2006-	Member: Advisory Board for the NIA CALERIE study
2009-	Member: Advisory Board for the Healthy Aging NIA-PO1 program
2009-2010	Member: National Diabetes Centers Executive Committee

Grant Study Sections

VA Merit Review Study Section Member 1995-
NIH GCRC study section Ad Hoc Reviewer 1995-
Allegheny University Grant Program Ad hoc reviewer 1996-9
Doris Duke Foundation Study Section Member 1997-9
NIDDK Research Centers of Excellence in Urology Ad Hoc reviewer 1997-
Glaser Pediatric Research Network fellowship Grants 1999-
Canadian Cancer Society Study Section Member 2000-
NIDDK Urology Special Emphasis Programs 2003-
NIDDK Urology Research Study Section Member 2003
Chair, UCLA/UCSD DERC P&F grant study section 2003-
NCI Site visit study section member 2004
NIA Proteomics and Aging Study Section 2004
NCI Oncology Cell Tissue Biology PO1 Study Section 2005-
NCI Tumor Cell Biology Study Section 2006-
NIDDK GI MCB Study Section 2006-
NCI P01 Discovery and Development SEP Study Section 2006-
NIA PO1 Special Study section 2007-
NIA NAME study Section 2008-
RC1/RC2 reviewer 2009
AFAR Grant reviewer 2009-

Congress Organizing Committees

Second International Symposium on Prostate Growth 1995
2nd International Growth Forum 1996
3rd International Growth Forum 1997
Fifth International IGF-99 Symposium 1999
The IGF in Cancer Symposium, Boston 1999
The GRS Consensus Meeting on GHD, Eilat 1999
Third International IGFBP Symposium, Sydney Australia 2000
GH Research Society Meeting Gothenburg 2000
The GRS Consensus Meeting on GH safety, Keswick 2000
The joint IGF Society and GH Research Society Meeting Boston 2002
The Nobel Institute IGFBP Symposium, Stockholm 2003
The 2nd joint IGF Society and GH Research Society Meeting, Cairns 2004
The 3rd joint IGF Society and GH Research Society Meeting, Kobe 2006
Chair: The LWPES/ESPE/GRS Consensus Meeting on ISS, Los Angeles, 2007
The 4th joint IGF Society and GH Research Society Meeting, Genova, 2008
Chair: The First Western DERC Awardee Conference, La Jolla 2009
The 5th joint IGF Society and GH Research Society Meeting, New York, 2010
Chair: The GRS Consensus Meeting on IGFD, Los Angeles, 2011

Membership in Professional and Scientific Societies (and offices held):

Society for Pediatric Research (elected 1995)
American Pediatric Society (elected 2006)
International IGF Society (*Director of Electronic Communication*)
Lawson Wilkins Pediatric Endocrine Society (*Member, Various Committees*)
Growth Hormone Research Society (*Executive Council Member*)
Association of Program Directors in Endocrinology (*Board Member for Pediatrics*)
Endocrine Society (*Member, Various Committees*)
American Academy of Pediatrics,
American Federation for Clinical Research
American Diabetes Association,
Juvenile Diabetes Foundation
American Association for Cancer Research

Scientific Advisory Boards

Abbott, Allergan, Ambrex, Amgen, Ardana, Arizeke, Bayer, Bristol Myers Squibb,
Beckman Coulter, Cephalon, Chyron, Diagnostic Systems Laboratories, Dyax, Eli
Lilly, EMD-Serono, Epigenetics, Genentech, Genzyme, Glaxo Smith Klein, GLG,
HGSI, Injex, Insmad, Ipsen, Merck, Novo Nordisk, Ontherix, Pfizer, Protigen,
Specialty Laboratories, Takeda, Tercica.

Founder Cohbar LLC.

Editorial Positions:

Associate Editor	2003-11	<i>Pediatric Research</i>
Associate Editor	2006-10	<i>Growth, Growth Hormone, & Metabolism</i>
Associate Editor	2006-9	<i>PLoS Computational Biology</i>
Associate Editor	2008-12	<i>Journal of Pediatric Endocrinology</i>

Editorial Board Member:

1995-7	<i>Growth Regulation</i>
2009-13	<i>Journal of Clinical Endocrinology and Metabolism (3rd term)</i>
1997-12	<i>Growth Hormone and IGF Research (3rd term)</i>
1999-14	<i>Molecular Genetics and Metabolism (3rd term)</i>
2000-1	<i>YourDoctor.com (Diabetes Section Editor)</i>
2001-12	<i>Journal of Pediatric Endocrinology & Metabolism</i>
2001-6	<i>Cancer Biology and Therapy</i>
2001-7	<i>Biocritique</i>
2002-10	<i>Journal of Clinical Pediatric Endocrinology (2nd term)</i>
2002-6	<i>Endocrinology</i>
2006-8	<i>Growth and Genetics</i>

Reviewer (Partial list): *New England Journal of Medicine, Lancet, Journal of Clinical Investigation, Journal of Biological Chemistry, JAMA, Journal of the National Cancer Institute (JNCI), Proceedings of the National Academy of Sciences (PNAS), Genes & Development, Diabetes, Molecular Endocrinology, Cancer Research, FASEB, PLoS Biology, Molecular and Cellular biology,*

Commentator: *Yearbook of Pediatrics, Journal of National Cancer Institute, International Growth Monitor, Pediatric Research, Endocrine News, Endocrine today.*

Academic Committees at UCLA

- 1999- Research Advisory Committee
- 1999- Grand Rounds Committee
- 2000- UCLA Comprehensive Diabetes Center Executive Committee
- 2000- Committee on Appointments and Promotions (Ad-hoc Member)
- 2001- General Clinical Research Center Advisory Committee
- 2002- DERC (Diabetes & Endocrinology Research Center) Executive Committee
- 2003- Program Directors Committee

Mentor/PI on Training Grants: - (total direct costs)

1993-1995 NRSA for L Katz "IGFs in the beta cell" \$66,000
1995-1996 LWPES fellowship for L Katz "IGF and the beta cell survival" \$35,000
1996-1999 CAP Award for L Katz "IGFs in the treatment of diabetes" \$270,000
1995-1997 NRSA for R Rajah "Growth factors in the airway" \$66,000
1997-1999 CHRC Award for R Rajah "IGFBP-3 in the prostate" \$35,000
1994-1996 Genentech Foundation Award: Solberg "GH treatment in Crohn's" \$35,000
1996-1997 NRSA for S Weinzimer "IGFBP partners" \$33,000
1997-1998 LWPES fellowship for S Weinzimer "Cloning IGFBP-3 partners" \$35,000
1998-1999 CHRC Award for S Weinzimer "Transferrin – IGFBP-3 interactions" \$35,000
1997-1998 NRSA for A Grimberg "IGFBPs and apoptosis" \$66,000
1998-1999 LWPES fellowship for A Grimberg "IGFBP-3 mediates p53 effects" \$35,000
1998-1999 NRSA for R Ferry "IGFBP-3 in the beta cell" \$66,000
1999-2000 LWPES fellowship for R Ferry "IGFBP-3 in type 1 diabetes" \$35,000
2000-2001 CHRC Award for R Ferry "IGFBPs in the beta cell" \$50,000
2001-2006 KO8 Award for R Ferry "Growth factors in beta cells" \$600,000
1997-1998 NRSA for M Shim "IGFBPs and insulin resistance" \$33,000
2000-2002 Glaser-GPRN fellowship for M Shim "GH treatment of CP" \$112,000
2000-2002 Nutrition center grant for S Franklin "Obesity and IGFBP-1" \$66,000
1999-2000 NRSA for L Wetterau "Activation of telomerase by IGFs" \$35,000
2000-2001 LWPES fellowship for L Wetterau "IGFs and telomerase" \$35,000
2001-2003 Giannini Award for K Lee "TR3 and IGFBP-3" \$80,000
2002-2003 NRSA for K Bharucha "IGFBP-3 regulation of glucose transport" \$70,000
2003-2005 PSDP for K Bharucha "IGFBPs in the regulation of insulin action" \$140,000
2003-2005 K12 for KW Lee "IGFBP-3 and Nur77" \$225,000
2004-2006 Genentech Foundation Award: Park "GH adjustment algorithm" \$100,000
2005-2007 DOD Fellowship Award for L Cobb "IGFBP-3 Phosphorylation" \$180,000
2005-2006 LWPES fellowship for J Yang "GH-IGF system in IUGR" \$35,000
2005-2006 LWPES Scholar Award for KW Lee "IGFBP-3 action" \$35,000
2005-2006 NRSA fellowship for R Randhawa "Epigenetics of IGF2 IUGR" \$40,000
2006-2007 NRSA fellowship for J Ching "Humanin in cancer" \$45,000
2006-2009 DOD Career Development Award for KW Lee "IGFBP-3 in CaP" \$500,000
2006-2007 ESPE Sabbatical grant for I Netchine "IGF & Fetal growth" \$50,000
2008-2009 NRSA fellowship for J Keni "regulation of humanin kinetics" \$50,000
2008-2009 NRSA fellowship for P Hoang "Humanin Rx of T1DM" \$50,000
2009-2010 NRSA fellowship for E Hosono "SHLPs in diabetes" \$50,000

Principal Investigator of Grants: (Past) - (total direct costs)

1989-1991 Juvenile Diabetes Foundation "IGF-I Therapy in Diabetes" \$60,000
 1990-1992 American Diabetes Association "IGF-I Treatment of NIDDM" \$70,000
 1991-1992 National Organization for Rare Diseases "IGF-I in Laron Syndrome" \$30,000
 1991-1992 LWPES "Transfection Model of IGFBP-3" \$35,000.
 1992-1994 CHRC Award "Biological Actions of IGFBPs" \$70,000
 1992-1996 Novo Foundation: "Multi-Center GH Dose Response Study" \$250,000
 1992-1996 NIH NCI RO1 CA58110 "The IGF axis in prostate carcinogenesis" \$500,000
 1993-1996 NIH 1RO1 DK47591 "IGF axis abnormalities in BPH" \$400,000
 1993-1996 ADA Career Development Award "The IGF axis in the beta cell" \$300,000
 1994-1996 Genentech Foundation "IGFBP transgenic mice" \$90,000
 1995-1999 FDA-RO1-01181 "IGF-I therapy of Congenital Hyperinsulinism" \$300,000
 1996-2001 NIH 1P50 HL 56401 "IGFs in Lung Development and BPD" \$780,000
 1996-2001 NIH 2RO1 DK47591 "IGF Axis Abnormalities in BPH" \$580,000
 1999-2002 ACS TPRN-N5 "IGFBP-3 in Prostate Apoptosis" \$225,000
 2000-2002 Pfeiffer Foundation "*In vitro* Models of Prostate Cancer" \$75,000
 1999-2002 JDFI "Novel Approaches to Preventing Diabetes Complications" \$300,000
 1999-2003 DOD CS-22982 "Signaling pathways in Prostate Cancer" \$480,000
 1998-2003 NIH 1RO1 AI40203 "The IGF axis in asthma" \$750,000
 1999-2003 CaP CURE Award "The IGF/IGFBP-3 axis in CaP" \$300,000
 2000-2003 NIH SBIR Award (with Celtrix Inc) "IGFBP-3 Therapy of Cancer" \$300,000
 2001-2003 Cerebral Palsy Foundation "GH therapy in Cerebral Palsy " \$100,000
 2001-2003 Genentech Foundation "GH abnormalities in Cerebral Palsy " \$80,000
 2000-2004 NCI UO1-CA 84128 "Novel Models of Prostate Cancer" \$360,000
 2000-2004 P30 AG16570 "UCLA Alzheimer's Disease P&F" \$30,000
 2001-2004 PNU "GEM Research Center Grant" \$300,000
 2001-2005 Novo "IGF-based dose titration of GH " National PI \$100,000
 2005-2007 NIH R21 CA 121220 Humanin in Prostate Cancer \$300,000
 2001-2006 NIA R01AG20954 Genomic and non-genomic actions of IGFBP-3 \$900,000
 2006-2007 Pfizer "GH Rx of a mouse model of SGA " \$50,000
 2006-2007 Eli Lilly "Development of a D3GHR Chemotyping assay " \$50,000
 2006-2007 Amgen "IGF1R blockade in prostate cancer " \$200,000
 2006-2007 JDRF Idea Development "Prevention of diabetes with humanin" \$125,000
 2003-2008 1R01CA100938 "IGF-I: a nutritionally regulated target in prostate cancer" \$1,000,000
 2005-2008 DOD PC050485 "Humanin: a novel therapeutic target in prostate cancer" \$375,000

Principal Investigator of Grants: (Active)

2004-2010	NICHD R01HD047013 PI: Pinchas Cohen "The Role of IGF2 in Fetal Growth Restriction" Total direct costs: \$1,200,000
2002-2012	NCI P50CA92131 SPORE in Prostate Cancer PI: R Reiter, Total direct costs: \$7,200,000 Dr. Cohen leads a project on IGFBP-3 as a cancer therapy Total costs of Dr. Cohen's project: \$800,000
2003-2013	NIDDK 1P30 DK 063491 Diabetes & Endocrinology Research Center (DERC) Total direct costs: \$9,000,000 PI: J Olefsky, Dr. Cohen is the associate director of the DERC and directs the Pilot and Feasibility Program
2005-2010	NIA 2R01AG018381 PI: Nir Barzilai "Disregulation of glucose metabolism in aging" Total direct costs: \$1,000,000 Dr. Cohen leads a subcontract for \$175,000
2006-2011	NIA 1P01AG 027734 PI: Nir Barzilai (AECOM). "Role of genes in humans exceptional longevity" Total direct costs: \$10,000,000 Dr. Cohen leads a subcontract for \$750,000
2009-2013	NIA 1R01AG 034430 PI: Pinchas Cohen Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA) "A family of novel mitochondrially-encoded peptides and their role in aging" Total direct costs: \$800,000
2009-2014	NIGMS 1R01GM 090311 PI: Pinchas Cohen Transformative-RO1 "Novel Mitochondrially derived Peptides and Their Role in Health and Disease" Total direct costs: \$2,000,000

Major Teaching and Clinical Responsibilities:

1. Endocrine/Diabetes Attending: 4 months a year; Pediatric Endocrine Clinic: 1 afternoon a week.
2. Supervision and teaching of medical students, residents and clinical fellows.
3. Director, Pediatric Endocrine/Diabetes Research and Training Program.
4. Director: Transitional Course for Academic Pediatrics
5. Director Pilot and Feasibility Core UCLA/UCSD
6. Scientific mentor for graduate students and research fellows: (see below for selected list):

<u>Trainee's Name</u>	<u>Degree</u>	<u>Institution</u>	<u>(Year)</u>	<u>Position in Cohen Lab</u>	<u>Years supervised</u>	<u>Funding Source</u>	<u>Current Position</u>
Lorraine E.L. Katz*	M.D.	Columbia U.	1989	post-doc fellow	1992-1996	LWPES	As Pr U Penn
Roopa Rajah*	Ph.D.	U. of Maryland	1994	post-doc fellow	1994-1997	NRSA	Researcher World Bank
Michael Agus*	M.D.	U Penn	1995	student	1994-1995	U Penn	As Pr Harvard
Paulo Solberg	M.D.	U S.Paulo.	1991	fellow	1994-1997	Gen. F.	As Pr URDJ
Tara Beers*	Ph.D.	U Penn	1998	PhD student	1995-1998	NRSA	UT (fellow)
S Weinzimer*	M.D.	Yale	1992	fellow	1995-1998	LWPES	As Pr Yale
Adda Grimberg*	M.D.	Cornell	1992	fellow	1996-1999	LWPES	As Pr U Penn
Robert Ferry*	M.D.	UT	1994	fellow	1997-2000	LWPES	As Pr UTSA
Bing Liu	M.D.	Beijing Uni	1997	fellow	1998-2001	NIH	As Res UCLA
Melanie Shim	M.D.	Stanford	1995	fellow	1999-2001	GPRN	Adjunct Ass Prof UCLA
Sherry Franklin	M.D.	UCLA	1996	post-doc fellow	1999-2002	Ins NRSA	Adjunct Ass Prof UCSD
Larry Wetterau	M.D.	UCLA	1995	post-doc fellow	1999-2001	LWPES	Adjunct Ass Prof Stanford
Michael Moore	M.D.	UCLA	2002	Med student	1999-2002	STAR	Harvard
Malik Francis	B.Sc.	UCLA	2000	student	2000-2004	NRSA	Berkeley PhD
Kuk-Wha Lee*	M.D., Ph.D.	Loma Linda	1997	post-doc fellow	2000-2003	Giannini Fellow.	Assist Prof UCLA
Kamal Bharucha*	M.D., Ph.D.	Yale	1998	post-doc fellow	2002-2005	PSDP	UCLA (instructor)
Maaria Ikonen	Ph.D.	Kuopio U	2002	fellow	2002-2005	FISC	As Pr Kupio
Omar Ali	M.D.	KEMC	1996	fellow	2002-2006	NIH	U Wisconsin (Asst Prof)
Patty Park	M.D.	NY medical Col.	2000	post-doc fellow	2003-2006	Genen. Found.	CSMC (fellow)

<u>Trainee's Name</u>	<u>Degree</u>	<u>Institution</u>	<u>(Year)</u>	<u>Position in Cohen Lab</u>	<u>Years supervised</u>	<u>Funding Source</u>	<u>Current Position</u>
Makoto Anzo	M.D.	Keio University.	1992	post-doc fellow	2003-2006	NIH	Keio (Professor)
Joshua Yang	M.D.	Texas Tech	2000	post-doc fellow	2003-2006	LWPES	USF (adjunct clin prof)
Kenichi Miyako	M.D., Ph.D.	Fukuoka U.	1999	post-doc fellow	2004-2007	NIH	Kyushu (As. Professor)
R. Randhawa	M.D.	Loma Linda	2001	post-doc fellow	2004-2007	LWPES	Adjunct assis Prof UCLA
Laura Cobb	Ph.D.	Cambridge	2004	post-doc fellow	2004-2007	DOD	As Pr UCLA
John Ching	M.D.	U Penn	2002	post-doc fellow	2005-2008	NRSA	Adjunct assis Prof UCLA
Hae Soon Kim	M.D.	Seoul U.	1980	Sabbatical	2005-2006	NIH	Professor
Satomi Koyama	M.D.	Tokyo U.	2000	post-doc fellow	2006-2009	NIH	UCLA (fellow)
Irene Netchine	M.D.	INSERM	1990	Sabbatical	2006-2007	INSERM	Professor
Phuong Hoang	M.D.	HoChiMin U	1994	post-doc fellow	2006-2009	NRSA	UCLA (fellow)
Haruo Mizune	M.D., Ph.D.	Nagoya U.	1996	post-doc fellow	2007-2008	NIH	Chiba (As. Professor)
Jyotsna Keni	M.D.	UCLA	2005	post-doc fellow	2007-2010	NRSA	UCLA (fellow)
Isabel Hernandez	M.D.	U of Chile	2000	post-doc fellow	2007-2008	NIH	As Pr Chile
Pauli Yamada	Ph.D.	UA	2007	post-doc fellow	2007-2010	NIH	UCLA (fellow)
Ed Hosono	M.D.	Johns Hopkins	2005	post-doc fellow	2008-2011	NIH	UCLA (fellow)
Brian Miyazaki	M.D.	UCLA	2006	post-doc fellow	2009-2012	NIH	UCLA (fellow)

* Denotes former trainee obtained an independent NIH grant

Major Invited Lectures:

- Feb 1992 WSPR. Carmel, California. David W. Smith Award Lecture:
"IGF-II Hyper-expression in Prostate Fibroblasts from BPH Patients".
- May 1992 Lawson Wilkins Society Meeting. Baltimore, Maryland. Lilly Award Lecture:
"Effects of IGFbps on Cell Growth".
- Aug 1992 2nd International Symposium on IGFbps. Opio, France.
"Transfection of the IGFbp-3 gene into Balb/c fibroblasts inhibits cellular growth".
- Sep 1992 International Symposium on the Biology of Prostate Growth. NIH, Maryland.
"The IGF axis in the prostate".
- May 1993 The National Meeting of the Spanish Endocrine Society. Seville, Spain.
"Growth Hormone Receptor Deficiency".
- Feb 1994 The Third International IGF Symposium. Sydney, Australia.
Lecture: "The IGF Axis in Prostatic Disease".
- Mar 1994 The American Urological association Annual Meeting. Houston TX.
"The physiology of the IGF Axis: Relevance to Urological Disease".
- May 1994 Workshop on GH and Catabolic Illness. Nice, France.
"Which actions of growth hormone are mediated by IGF-I and which are not".
- Mar 1995 The Fifth International Symposium on insulin and IGFs. Gainesville, Florida.
Lecture: "Co-regulation of smooth muscle by inflammatory agents and the IGF axis".
- Oct 1995 3rd International Symposium on IGFbps. Tübingen, Germany.
"IGFBP proteases - functional regulators of cellular growth".
- Dec 1995 The National Meeting of the Indian Endocrine Society. Ahmadabad, India.
"Growth Hormone and IGF Deficiencies"
- Mar 1996 International Symposium on the Biology of Prostate Growth. Washington DC.
"Proteases for the IGFbps: growth and the extracellular environment".
- Sep 1996 NIH Research Festival Symposium. Bethesda MD.
"Regulation of cell growth and death by IGFbps"
- Oct 1996 Cambridge Symposia Conference on Cell Cycle Control. Bolton Valley, VT.
"Regulation of cellular apoptosis by IGFbp-3".
- Nov 1996 ADA annual Freedman Symposium, New York NY.
"IGFBps: regulators of glucose and insulin metabolism".
- Mar 1997 Invited lecturer: Parapathetic Club.
"IGFBps as cell regulators".
- Apr 1997 8th hGH Symposium, Mannheim Germany.
"Dose response to GH therapy"

- Apr 1997 NIH Conference on Assessment of the GH/IGF-I axis in aging, Wash. DC.
"IGFBP-3 and prostatic neoplasia"
- Nov 1997 The Forth International IGF Symposium. Tokyo Japan.
Lecture: "New insights into IGFBP-3 action".
- Jun 1998 Endocrine Society Plenary Symposium. New Orleans LA.
"Cell Regulatory Function of IGFBP-3"
- Aug 1998 Cap CURE Annual Meeting. Lake Tahoe, CA
Lecture: "Novel aspects of prostatic IGF Biology"
- Sep 1998 Japanese Society of Pediatric Endocrinology Annual Meeting. Kyoto Japan.
Keynote Lecture: "Cell Regulatory Function of IGFBP-3"
- Oct 1998 Serono Symposium on GH. Amelia Island FL.
Lecture: "GH and diabetes"
- Nov 1998 Prostate Cancer Symposium. Naples FL
Lecture: "IGFBP-3 and prostatic neoplasia"
- Nov 1998 9th hGH Symposium, Copenhagen Denmark.
Lecture: "IGF, GH, and Prostate Cancer: Guilty by Association?"
- Feb 1999 Annual Kaplan Lecture. UCLA.
Lecture: "IGFs: past, present and future of diabetes?"
- Jun 1999 5th International Trans-Pacific Endocrine Symposium, San Diego.
Lecture: "New advances in IGF biology"
- Sep 1999 Annual Growth Hormone Symposium, Copenhagen, Denmark
Lecture: " Effects of dose and gender on GH responsiveness in GHD "
- Oct 1999 The GRS consensus meeting on growth hormone deficiency, Eilat, Israel.
"Algorithms for the diagnosis of GHD" and "optimizing GH therapy"
- Sep 1999 The First International Symposium on GH, IGF, and Cancer, Boston.
Lecture: "Cancer risk-reduction by Monitoring IGF-I during GH therapy"
- Nov 1999 The Fifth International IGF Symposium. Brighton, England.
Lecture: "IGFBP-3: new partners, new functions".
- Apr 2000 KIGS Symposium, Marrakech.
Lecture: "Optimizing and Monitoring GH Therapy"
- May 2000 HypoCCS Symposium, Sorrento, Italy.
Lecture: "IGF and Diabetes"
- May 2000 The GRS consensus meeting on Growth Hormone Safety, Keswick VA.
Lecture: "Epidemiology of GH and Cancer:"
- May 2000 The 6th International Growth Forum (IGF-VI), Boston MA.
Lecture: "The GH-Cancer connection"

- Aug 2000 Annual Pediatric Endocrine Symposium, Sapporo Japan.
Lecture: "The new new-new somatomedin hypothesis"
- Sep 2000 The IGF Cancer Symposium, Halle Germany.
Lecture: "Roles IGFBPs in cancer pathophysiology"
- Sep 2000 National Cooperative Growth Study meetings, San Francisco, CA.
Lecture: "Monitoring GH Therapy in the new millennium"
- Sep 2000 Cap CURE Annual Meeting. Lake Tahoe, CA
Lecture: "IGFBP-3: a potential therapy for cancer"
- Oct 2000 IGFBP2000 Symposium, Terrigal, Australia.
Lecture: "Nuclear IGFBPs"
- Nov 2000 ICE 2000, Sydney Australia.
Lecture: "GH, IGF and diabetes: safety implications for clinicians"
- Feb 2001 The National meeting of US Association of Pharmacists, Pasadena, CA.
Lecture: "New paradigms in GH therapy"
- Mar 2001 Annual German Growth Study meeting, Heidelberg, Germany.
Lecture: "An update on GH safety"
- Apr 2001 The Second Trans-Pacific GH Symposium, Honolulu, HI.
Lecture: "New approaches to GH dosing"
- May 2001 International Growth Symposium, Cancun, Mexico.
Lecture: "What are IGFBPs doing in the nucleus?"
- Jul 2001 Pediatric Endocrine Review Course, Montreal Canada.
Lecture: "The GH-IGF axis: clinical implications"
- Aug 2001 Annual Japanese Growth Study meeting, Tokyo, Japan.
Lecture: "Growth hormone, insulin-like growth factors, relation to diabetes"
- Feb 2002 International Aging Male Symposium Berlin Germany.
"Safety of GH therapy: IGF and cancer revisited".
- Apr 2002 International Growth Hormone Symposium, Budapest, Hungary.
"IGFBPs, what do they do and why should we monitor them".
- May 2002 NIH meeting on GH, IGF and Aging.
"Role of the GH-IGF-IGFBP system in carcinogenesis".
- May 2002 ACVIM Annual Meeting, Plenary Lecture, Dallas TX.
"IGFs and IGFBPs in health and disease".
- July 2002 Neuroscience Grand Rounds, KEIO University, Tokyo.
"A proposed role for IGFBP-3 in Alzheimer's disease"
- Aug 2002 MD Anderson Oncology Grand Rounds, Houston, Texas.
"IGFBPs and cancer: roles in pathogenesis and treatment".

- Oct 2002 Endocrinology of Aging Symposium, Munich, Germany
"Should we be concerned about malignancy in GH recipients?"
- Oct 2002 National Cooperative Growth Study Annual Meeting, Chicago, IL
"Beyond weight-based dosing for GH"
- Oct 2002 AAP CME Symposium: "Growth hormone in the 21st century", Boston, MA
Organizer and Lecturer: "New indications for GH therapy"
- Nov 2002 Functional Roles of IGFBPs Symposium, Tübingen, Germany.
"Clinical potential of IGFBP-3".
- Dec 2002 NCI Prostate SPORE Annual meeting, San Francisco.
"IGFBP-3 and its role in prostate cancer".
- Mar 2003 International Growth Hormone Symposium, Lisbon Portugal.
"IGFs in intra-uterine growth retardation".
- Mar 2003 Annual German Endocrine Society Meeting, Munich, Germany.
Lecture: "GH-IGF and cancer risk"
- Apr 2003 NIH apoptosis and aging workshop, Bethesda MD.
Lecture: "intra-nuclear roles of IGFBP-3 in apoptosis"
- May 2003 SPR meeting, Seattle, WA, Plenary Symposium on peri-natal origins of disease.
Lecture: "implications of early childhood growth on adult cancer risk"
- May 2003 Serono Symposium on Growth Hormone in HARS, Chicago, IL
Lecture: "IGFBP-3: a GH-dependent anticarcinogenic molecule"
- May 2003 Genesis Meeting, Vancouver Canada.
Lecture: "Revisiting the GH-cancer connection"
- May 2003 ANSCG Annual Meeting Key Biscayne FL.
Lecture: "IGFs and longevity"
- June 2003 Endocrine Society Annual Meeting; Philadelphia PA.
Meet the Professor Lecture: "GH therapy optimization"
- July 2003 Pediatric Grand Rounds Asahikawa University, Japan.
Lecture: "Small old mice: is size and IGF related to life span?"
- Aug 2003 The Fifth International IGFBP Symposium, Stockholm, Sweden.
Plenary Lecture: "The Ying and Yang of IGFBP-3"
- Sep 2003 Annual Meeting of the Latin Society for Pediatric Endocrinology, Cancun, Mexico.
Plenary Lecture: "IGFBPs in health and disease"
- Sep 2003 ESPE Annual Meeting, Ljubljana, Slovenia.
Plenary Lecture: "The GH-IGF axis and cancer"
- Sep 2003 Annual Meeting of the Asian Society for Pediatric Endocrinology, Seoul, Korea.
Plenary Lecture: "IGF measurements in the management of GHD"

- Oct 2003 SGA Summit, Rapallo, Italy
Lecture: "Safety of GH treatment of SGA"
- Nov 2003 Gerontological Society of America Annual Meeting, San Diego, CA.
Lecture: "IGF and longevity in humans"
- Dec 2003 The Annual Meeting of the Asian Endocrine Society, Singapore.
Plenary Lecture: "Clinical and molecular aspects of the IGFBPs"
- Jan 2004 KIGS Expert Meeting on GH therapy, Paris, France.
Lecture: "IGF-based dose adjustment in GH therapy"
- May 2004 LWPES Meeting san Francisco, Satellite Symposium on Growth
Lecture: "Cancer and GH"
- Jun 2004 Endocrine Society, New Orleans, LA
Meet the Professor Lecture: "Diagnostic Approach to the Short Patient"
- Jun 2004 Annual Somatomedin Club, New Orleans, LA
Keynote Lecturer
- Jun 2004 Transpacific Lecture, Satellite Symposium to ENDO2004 New Orleans, LA
Lecture: "Humanin – a new growth factor"
- Sep 2004 Endocrine Grand Rounds, Boston Children's Hospital/Harvard University Boston MA
Lecture: "Hormonal Regulation of Cancers"
- Oct 2004 NCGS Annual meeting, Phoenix, AZ
Lecture: "The role of IGF assays in GH therapy of ISS"
- Jan 2005 Gordon Research Conference Ventura CA
"Mechanisms of action of IGFBPs"
- Mar 2005 Japanese Endocrine Society Meeting, Sapporo Japan
Lecture: "IUGR and the IGF system"
- April 2005 The Burnham Institute Seminar Series
Lecture: "IGFBP-3 as an apoptotic factor"
- June 2005 Endocrine Society Annual meeting Symposium. San Diego, CA
"IGF-based Dosing Optimizes the Efficacy of GH Therapy"
- Jul 2005 NICHD grantee meeting, Bethesda MD
Lecture: "IGF2 epigenetics and fetal growth"
- Aug 2005 Fred Hutchinson Cancer Center Grand Rounds Seattle, WA
Lecture: "The IGF axis as a target for prostate cancer: nutritional implications"
- Sep 2005 ESPE/LWPES Joint meeting. Lyon, France
"Is ISS really idiopathic?"
- Oct 2005 Melbourne University Science Symposium. Melbourne, Australia
"Humanin: a neurotrophic factor or an insulin sensitizer?"

- Jan 2006 Gordon Research Conference Ventura CA
"IGF-related molecules in longevity and aging"
- Jan 2006 SPORE Annual Meeting, Houston Texas
"Mechanisms of IGFBP-3 actions as an anti-prostate cancer agent"
- Mar 2006 Israeli Endocrine Society Meeting, Tel Aviv Israel
Keynote Lecture: "The promise of IGF therapy"
- Apr 2006 USC Symposium on Aging and Cancer, Los Angeles
Lecture: "the IGF system in longevity and aging related diseases"
- May 2006 LWPE/ APS-SPR Meeting, San Francisco
Lecture: "IGF Deficiency – treating with IGF-based GH dosing"
- May 2006 NIH Conference on Nuclear Receptors and Aging
Lecture: "IGFBP-3 interactions with nuclear receptors"
- Jun 2006 Endocrine Society Annual meeting, Boston
CME Symposium on IGF-Deficiency; Lecture: "Is ISS really idiopathic?"
- Jul 2006 ESPE Summer School, Rotterdam
"From molecular discovery to functional biology: the story of humanin"
- Nov 2006 4th International Joint Meeting of the GRS and IGF-Society, Kobe, Japan
"Chemotype: the Interface Between Genotype and Phenotype"
- Dec 2006 Chinese Endocrine Society Annual Meeting, Hong Kong
"New Advances in Growth Therapies"
- Mar 2007 NCGS Annual meeting, Los Angeles, CA
Lecture: "IGF measurements in the management of growth disorders"
- Apr 2007 Annual Spring Endocrinology Symposium, Kyoto, Japan
Lecture: "Advancements in GH therapy"
- May 2007 Genesis meeting, Paris, France
Lecture: "Why we need to continue using GH stimulation tests"
- May 2007 American Pediatric Society Annual meeting, Toronto CA
APS Best Science Award Lecture: "Unraveling the functions of IGFBPs"
- Jun 2007 Endocrine Society Annual meeting, Toronto CA
Plenary Lecture: "The GH IGF axis in aging and Longevity"
- Oct 2007 ISS Consensus Workshop, Santa Monica, CA
Overview Lecture: "Optimizing GH therapy in ISS"
- Nov 2007 Fetal Growth Retardation Grantee Meeting, NIH, Bethesda MD
Lecture: "IGF2 and humanin in fetal growth"
- Dec 2007 AFAR symposium on Aging. Genome maintenance, and Metabolism
Lecture: "Growth factors, aging, and cancer"

- Jan 2008 The Winter GH Symposium, Seefeld Austria
Lecture: IGF-based dosing- from adult to pediatric and back to adult Endocrinology
- Feb 2008 CHORI/Children's Oakland Grand Rounds
Lecture: Novel Mitochondrial peptides control metabolism and survival
- May 2008 KIGS Annual Meeting, Honolulu Hawaii
Lecture: Is there a relationship between GH and Cancer?
- May 2008 LWPES/PAS Annual Meeting, Honolulu Hawaii
Lecture: Consensus Statement on ISS
- May 2008 40th International Symposium of Growth Hormone, Paris France
Lecture: Unresolved Issues in the Management of ISS
- Sept 2008 4th Joint Meeting of the GRS & IGF Societies, Genova, Italy
Lecture: ISS, IGF, and the new biology of the GH-IGF system
- Oct 2008 15th Prostate Cancer Foundation Meeting, Lake Tahoe
IGFs Integrate Genetic and Environmental Signals to Control Longevity and Health
- Dec 2008 Annual Meeting of the Israeli Pediatric Endocrine Society
Lecture: new insights into the biology of growth
- Mar 2009 IMED Seminar Series UCLA
Novel Mitochondrial Derived Peptides in Health and Disease
- Apr 2009 Milken Institute Global Conference
Lecture: Strategies for enhancing health span and life span
- Aug 2009 The Belinson Hormone Symposium, Tel Aviv, Israel
Lecture: Novel Mitochondrial Peptides
- Sep 2009 ESPE/LWPES Joint Meeting, New York
Lecture: GH, IGF, Aging and Longevity
- Sep 2009 Annual AFAR meeting, Santa Barbara
Keynote Lecture: Mitochondrial-derived peptides: retrograde signals for metabolism
- Nov 2009 Chilean Endocrinology Congress, Santiago, Chile
Symposium Plenary Lecture: Humanin: a novel treatment for diabetes
- Dec 2009 The Annual Kroc Professorship and Lecture, Stanford University
Lecture: Novel Mitochondrial Peptides and their role in aging

Patents:

- Humanin analogues as a treatment for type II diabetes
- Humanin analogues as a treatment for type I diabetes.
- SHLPs for the treatments of neurodegenerative and metabolic diseases.
- SHLP-6 for the treatment of cancer

Media Mentions and Appearances:

New York Times
Los Angeles Times
BBC
Scientific American
ABC news
Washington Post
Fox News

Bibliography:**Research Publications, Peer Reviewed:**

1. Karnieli E, Cohen P, Barzilai N, Ish-Shalom Z, Armoni M, Rafaelov R, Barzilai D: Insulin resistance in Cushing syndrome. *Horm Metabol Res* 17:518, 1985.
2. Barzilai N, Cohen P, Barzilai D, Karnieli E: Increased insulin responsiveness and insulin clearance in thyrotoxicosis. *Isr J Med Sci* 21:722, 1985.
3. Cohen P, Barzilai N, Bar-Ilan R, Yassin K, Karnieli E: Lack of suppression of insulin secretion by hyperinsulinemia in a patient with an insulinoma. *J Clin Endocrinol and Metab* 63:1411, 1986.
4. Cohen P, Barzilai N, Barzilai D, Karnieli E: Correlation between insulin clearance and insulin responsiveness: studies in normal, obese, hyperthyroid, and Cushing syndrome patients. *Metabolism* 1986.
5. Karnieli E, Armoni M, Cohen P, Kantor Y, Rafaeloff R: Reversal of insulin resistance in diabetic rat adipocytes by insulin therapy. *Diabetes* 36:925, 1987.
6. Cohen P, Ariagno R, Tune B: Neonatal salicylism due to in utero aspirin overdose. *International Pediatrics* 4:352, 1989.
7. Cohen P, Harel C, Bergman R, Daud D, Pam Z, Barzilai N, Armoni M, Karnieli E: Insulin resistance and acanthosis nigricans: evidence for a post-receptor defect. *Metabolism* 39:1006, 1990.
8. Cohen P, Collart L, Prober CG, Fischer AF, Blaschke TF: Gentamicin pharmacokinetics in neonates undergoing extracorporeal membrane oxygenation. *Pediatr Infect Dis J* 9:562, 1990.
9. Szyzman P, Wolach B, Winaver J, Panett R, Cohen P, Shenkman L, Better OS: Nonazotemic hyperkalemia with renal and extra-renal defects in potassium transport: association with high levels of digoxin-like immunoreactive factor. *J Lab Clin Med* 116:315, 1990.
10. Cohen P, Barzilai N, Lerman A, Harel H, Szyzman P, Karnieli E: Insulin effects on glucose and potassium metabolism in-vivo: evidence for selective insulin resistance in humans. *J Clin Endocrinol Metab* 73:564-568, 1991.
11. Barzilai N, Cohen P, McIntyre N, Bar-Ilan R, Karnieli E: Increased insulin sensitivity in tumor hypoglycemia in a diabetic patient. *Am J Med Sci* 302:229-234, 1991.
12. Cohen P, Peehl DM, Lamson G, Rosenfeld RG: Insulin-like growth factors (IGFs), IGF receptors and IGF binding proteins in primary cultures of prostate epithelial cells. *J Clin Endocrinol Metab* 73:491-1991.
13. Barzilai N, Cohen P, Karnieli E, Einat R, Epstein O, Owan J, McIntyre N: In vivo insulin action in hepatocellular and cholestatic liver cirrhosis. *J Endo Invest* 14:727-735, 1991.
14. Hasegawa Y, Cohen P, Yorgin P, Rosenfeld RG: Characterization of urinary insulin-like growth factor binding proteins. *J Clin Endocrinol Metab* 74:830-835, 1992.

15. Cohen P, Graves HCB, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG: Prostate specific antigen (PSA) is an IGF binding protein (IGFBP-3) protease found in seminal plasma. *J Clin Endocrinol Metab* 75:1046-53; 1992.
16. Neely EK, Hintz RL, Parker B, Bachrach LB, Cohen P, Olney R, Wilson DW: Two-year treatment results of depot leuprolide acetate therapy for central precocious puberty. *J Pediatrics* 121:634-40, 1992.
17. Wilson DM, Dotson RJN, Neely EK, Cohen P, Hintz RL, Rosenfeld RG: A randomized trial of the effects of estrogen administration on serum growth hormone concentrations following stimulation with clonidine. *AJDC*, 147:63-6, 1993.
18. Cohen P, Peehl DM, Stamey TA, Wilson K, Clemmons DR, Rosenfeld RG: Elevated levels of insulin-like growth factor binding protein-2 in the serum of prostate cancer patients. *J Clin Endocrinol Metab*, 76:830-835, 1993.
19. Vaccarello MA, Diamond FB, Guevara-Aguirre J, Rosenbloom AL, Fielder PJ, Gargosky S, Cohen P, Wilson K, Rosenfeld RG. Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. *J Clin Endocrinol Metab*, 77:273-80, 1993.
20. Barzilai N, Barzilai D, Karnieli E, Cohen P: Correlation Between Glucose and Amino Acids Disposal in Healthy and Hyperthyroid Subjects. *Horm Metabol Res*, 25:382-5, 1993.
21. Cohen P, Lamson G, Okajima T, Rosenfeld RG: Transfection of the human IGF binding protein-3 gene into Balb/c fibroblasts inhibits cellular growth. *Molecular Endocrinol*, 7:380-386, 1993. **Also included the art for the Journal Cover**
22. Lee DY, Cohen P, Krensky AM, Rosenfeld RG, Yorgin PD: Insulin-like growth factor binding protein-3 (IGFBP-3) protease activity in the urine of children with chronic renal failure. *Pediatr Nephrol*, 1993.
23. Cohen P, Peehl DM, Graves HCB, Rosenfeld RG: Biological effects of prostate specific antigen (PSA) as an IGF binding protein-3 (IGFBP-3) protease. *J Endocrinol*, 142:407-415, 1994.
24. Cohen P, Peehl DM, Hintz RL, Rosenfeld RG: Insulin-like growth factor axis abnormalities in cultures of prostate stromal cells from patients with benign prostatic hypertrophy. *J Clin Endocrinol Metab*, 79:1410-1415, 1994.
25. Lee DY, Oh Y, Cohen P, Rosenfeld RG: Insulin-like growth factor binding protein-3 (IGFBP-3) protease activity in the urine of patients with chronic renal failure. *J Clin Endocrinol Metab*, 79:1376-1994.
26. KO Lee, Y Oh, P Cohen, DM Peehl, RG Rosenfeld. Identification of IGFBP-5 protease activity in human seminal plasma. *J Clin Endocrinol Metab*. 79:1367-1372. 1994.
27. Noveral J, A Bhala, Grunstein M, P Cohen. The insulin-like growth factor axis in airway smooth muscle cells. *American Journal of Physiology*, 267:L761-5, 1994.
28. Fielder PJ, Rosenfeld RG, Graves HCB, Grandbois K, Maack CA, Sawarama Y, Ogawa Y, Sommer A, Cohen P: Biochemical Analysis of PSA-proteolyzed IGFBP-3. *Growth Regulation*, 4:164-72. 1994.

29. Cohen P, Barzilai N, Karnieli E: Suppression of insulin secretion by C-peptide infusion in man. *Isr J Med Sci* 31:284-288;1995.
30. Hasegawa T, Cohen P, Rosenfeld RG: Characterization of the IGF axis in TM-3 Leydig cells. *Growth regulation* 5:151-9; 1995.
31. B Valentinis, A Bhala, R Baserga, P Cohen. Transfection of the human insulin-like growth factor (IGF) binding protein-3 gene into fibroblasts from IGF-receptor gene-targeted mice inhibits cellular growth. *Molecular Endocrinology* 9:361-367, 1995. **Also included the art for the Journal Cover**
32. Wilson K, Fielder PJ, Guevara JA, , Cohen P, Rosenbloom A, Rosenfeld RG: Long term effects of IGF-I therapy on serum IGFs and IGFBPs in adolescents with GHRD. *Clinical Endocrinology*, 42:399-407, 1995.
33. P Cohen, A Bhala, Noveral J, Grunstein M. The effects of Leukotriene D₄ on the proliferation of airway smooth muscle cells are mediated by modulation of the IGF axis. *American Journal of Physiology* 296:L151-157; 1995.
34. Agus M, Katz L, Smith M, Hintz RL, Meadows A, Cohen P. Non islet cell tumor hypoglycemia in a child with neuroblastoma: response to GH therapy. *Journal of Pediatrics*, 127:403-7; 1995.
35. Katz L, Hintz RL, Liu F, Cohen P. Non islet cell tumor hypoglycemia in a child with neuroblastoma: analysis of the IGF axis. *Journal of Clinical Endocrinology and Metabolism* 81:1141-6; 1996.
36. Rajah R, Bhala A, Nunn S, Peehl D, Cohen P. Murine 7S nerve growth factor is an insulin-like growth factor binding protein protease. *Endocrinology* 137: 2676-2682; 1996.
37. Hawkins M, Barzilai N, Chen W, Angelov I, Hu M, Cohen P, Rossetti L: Increased Hexosamine availability similarly impairs the action of insulin and IGF-1 on glucose disposal. *Diabetes*. 45:1734-1743; 1996.
38. Rajah, R, Nunn S, Herrick D, Grunstein MM, Cohen P. LTD-4 induces matrix metalloproteinase-1, which functions as an IGFBP protease in airway smooth muscle cells., *American Journal of Physiology* L1014-1022; 1996.
39. Katz LEL, A Bhala, RL Hintz, P Cohen. IGF-II, IGFBPs and IGF-R in pancreatic beta cell lines. *Journal of Endocrinology* 152:455-464; 1997.
40. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. *Journal of Biological Chemistry* 272: 12181-12188; 1997.
41. Nunn S, Peehl DM, Cohen P: Cathepsin D is an acid activated IGFBP protease found in seminal plasma and produced in normal and malignant prostate epithelial cells. *Journal of Cellular Physiology* 171:196-204; 1997.
42. Gil-Ro Han, David F. Dohi, Ho-Young Lee, Roopmathy Rajah, Garrett L. Walsh, Waun Ki Hong, Pinchas Cohen, Jonathan M. Kurie. All-trans-retinoic acid increases TGF- β 2 and insulin-like growth factor binding protein-3 expression through a retinoic acid receptor- α -dependent signaling pathway. *Journal of Biological Chemistry* 272:13711-9; 1997.

43. Dong G, Rajah R, Vu T, Hoffman AR, Rosenfeld RG, CT Roberts Jr., Peele DM, Cohen P: Decreased expression of the Wilm's tumor suppressor gene WT1 and increased IGF-II and IGF-1R in the prostatic stroma of patients with benign prostatic hyperplasia. *Journal of Clinical Endocrinology and Metabolism*, 82:2198-2203; 1997.
44. Katz LEL, Satin-Smith M, Collett-Solberg P, Thornton PS, Baker L, Stanley CA, Cohen P. IGF binding protein-1 levels in the diagnosis of hypoglycemia caused by hyperinsulinism *Journal of Pediatrics* 131:193-9; 1997.
45. Thomas LN, Cohen P, Douglas RC, Lazier C, Rittmaster RS. IGF binding protein 5 is associated with involution of the ventral prostate in castrated and finasteride-treated rats. *Prostate* 1998 ; 35:273-278.
46. Bhala A, Harris MC, Zirin S, Corcoran L, Cohen P. Insulin-like growth factor axis parameters in sick hospitalized neonates. *Journal of Pediatric Endocrinology and Metabolism* 11, 451-459, 1998.
47. Collett-Solberg PF, Nunn SE, Beers-Gibson T, Cohen P. Identification of novel high molecular weight IGFBP-3 association proteins in human serum. *Journal of Clinical Endocrinology and Metabolism* 83:2843-2850, 1998.
48. Hasdai D, Rizza RA, Holmes DR Jr, Richardson DM, Cohen P, Lerman A. Insulin and insulin-like growth factor-I cause coronary vasorelaxation in vitro. *Hypertension* 1998; 32:228-234.
49. Hasegawa T, Hasegawa Y, Rosenfeld RG, Cohen P. IGFBP-4 accumulation is negatively correlated with growth rate in TM-3 cells. *Growth Hormone and IGF Research* 1998; 8:277-282.
50. Katz LE, Satin-Smith MS, Collett-Solberg P, Baker L, Stanley CA, Cohen P. Dual regulation of insulin-like growth factor binding protein-1 levels by insulin and cortisol during fasting. *Journal of Clinical Endocrinology and Metabolism* 83:4426-4430; 1998.
51. Miao ZR, Lin TK, Bongso TA, Zhou X, Cohen P, Lee KO. Effect of insulin-like growth factors (IGFs) and IGFBPs on in vitro sperm motility. *Clin Endocrinol (Oxf)* 1998; 49:235-9.
52. Barzilai N, She L, Liu BQ, Vuguin P, Cohen P, Wang J, Rossetti L. Surgical removal of visceral fat reverses hepatic insulin resistance. *Diabetes* 1999; 48:94-98
53. Rajah R, Nachajon RV, Collins MH, Hakonarson H, Grunstein MM, Cohen P. Elevated levels of the IGF-binding protein protease MMP-1 in asthmatic airway smooth muscle. *Am J Respir Cell Mol Biol* 1999; 20:199-208.
54. Grimberg A, Satin Smith M, Cerri R, Cohen P. The "two-bag system" for variable intravenous dextrose and fluid administration: Benefits in diabetic ketoacidosis management. *J Pediatr* 134:376-380;1999.
55. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. *Cancer Res* 1999; 59:2203-9.
56. Hasdai D, Nielsen MF, Rizza RA, Holmes DR Jr, Richardson DM, Cohen P, Lerman A. Attenuated In vitro coronary arteriolar vasorelaxation to insulin-like growth factor I in experimental hypercholesterolemia. *Hypertension* 1999; 34:89-95.

57. Beers-Gibson T, Cohen P. IGFBP proteolytic activity of the neutrophil proteases cathepsin G and elastase. *J GH & IGF Res* 9: 241-253; 1999.
58. Katz LEL, Ferry RJ Jr, Stanley CA, Collett-Solberg PF, Baker L, Cohen P. Suppression of insulin over-secretion by subcutaneous recombinant human IGF-I in children with congenital hyperinsulinism due to defective β -cell sulfonylurea receptor. *The Journal of Clinical Endocrinology & Metabolism* 1999; 84:3117-3124.
59. Sutkowski DM, Goode RL, Baniel J, Teater C, Cohen P, McNulty AM, Hsiung HM, Becker GW, Neubauer BL. Growth regulation of prostatic stromal cells by PSA. *J Natl Cancer Inst* 1999; 91:1663-9.
60. R. Rajah, A. Khare, P.D.K. Lee, and P. Cohen. IGFBP-3 is partially responsible for high serum induced apoptosis of PC-3 prostate cells. *J Endocrinol* 1999; 163:487-94.
61. Thomas LN, Wright AS, Lazier CB, Cohen P, Rittmaster RS. Prostatic involution in men taking finasteride is associated with elevated levels of IGF-binding proteins (IGFBPs)-2, -4, and -5. *Prostate*. 2000; 42:203-10.
62. Cohen P, Nunn S, Peehl DM. Transforming growth factor-beta induces growth inhibition and IGF-binding protein-3 production in prostatic stromal cells: abnormalities in cells cultured from benign prostatic hyperplasia tissues. *J Endocrinology*. 2000; 164:215-223.
63. Izhar U, Hasdai D, Richardson DM, Cohen P, Lerman A. Insulin and insulin-like growth factor-I cause vasorelaxation in human vessels in vitro. *Coron Artery Dis* 2000;11:69-76.
64. Cohen P, Rajah R, Rosenbloom J, Herrick DJ. IGFBP-3 mediates TGF-beta1-induced cell growth in human airway smooth muscle cells. *Am J Physiol Lung Cell Mol Physiol*. 2000; 278:L545-L551.
65. Mannhardt B, Weinzimer SA, Wagner M, Fiedler M, Cohen P, Jansen-Durr P, Zwerschke W. Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3. *Mol Cell Biol* 2000; 20:6483-95.
66. Sueoka N, Lee HY, Wiehle S, Cristiano RJ, Fang B, Ji L, Roth JA, Hong WK, Cohen P, Kurie JM. IGF binding protein-6 activates programmed cell death in non-small cell lung cancer cells. *Oncogene* 2000; 19:4432-6.
67. Sueoka N, Lee HY, Walsh GL, Fang B, Ji L, Roth JA, LaPushin R, Hong WK, Cohen P, Kurie JM. Insulin-Like Growth Factor Binding Protein-6 Inhibits the Growth of Human Bronchial Epithelial Cells and Increases in Abundance with All-trans-Retinoic Acid Treatment. *Am J Respir Cell Mol Biol* 2000; 23:297-303.
68. Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, Cohen P. Direct Functional Interactions between Insulin-like Growth Factor-binding Protein-3 and Retinoid X Receptor-alpha Regulate Transcriptional Signaling and Apoptosis. *J Biol Chem* 2000; 275:33607-33613.
69. Boyle BJ, Zhao XY, Cohen P, Feldman D. Insulin-like growth factor binding protein-3 mediates 1alpha, 25-dihydroxyvitamin-D3 growth-inhibition in the LNCaP prostate cancer cell line through p21/waf1. *J Urol* 2001; 165:1319-24.

70. Weinzimer SA, Beers Gibson T, Collett-Solberg PF, Khare A, Liu B, Cohen P. Transferrin Is an Insulin-Like Growth Factor-Binding Protein-3 Binding Protein. *JCEM* 2001; 86:1806-13.
71. Cohen P, G Bright, AD Rogol, AM Kapplegaard, Rosenfeld RG. Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. *JCEM* 2002; 87: 90-98.
72. R Rajah, KW Lee, P Cohen. Insulin-like growth factor binding protein-3 (IGFBP-3) mediates TNF induced apoptosis: Role of Bcl-2 phosphorylation. *Cell growth & Differentiation* 2002; 13:163-71.
73. Lee HY, Chun KH, Liu B, Wiehle SA, Cristiano RJ, Hong WK, Cohen P, Kurie JM. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. *Cancer Res* 2002; 62:3530-7.
74. Grimberg A, Liu B, Bannerman P, El-Deiry WS, Cohen P. IGFBP-3 mediates p53-induced apoptosis during serum starvation. *Int. J. Oncol.* 2002; 21:327-35.
75. Moran A, Jacobs DR Jr, Steinberger J, Cohen P, Hong CP, Prineas R, Sinaiko AR. Association between the Insulin Resistance of Puberty and the IGF-I/Growth Hormone Axis. *J Clin Endocrinol Metab* 2002; 87:4817-20.
76. Ngo TH, Barnard RJ, Tymchuk CN, Cohen P, Aronson WJ. Effect of diet and exercise on serum insulin, IGF-I, and IGFBP-1 levels and growth of LNCaP cells in vitro. *Cancer Causes and Control* 2002; 13:929–935.
77. Franklin SL, Ferry RJ Jr, Cohen P. Rapid Insulin-Like Growth Factor (IGF)-Independent Effects of IGF Binding Protein-3 on Endothelial Cell Survival. *J Clin Endocrinol Metab* 2003; 88:900-7.
78. Moore MG, Wetterau LA, Francis MJ, Peehl DM, Cohen P. Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. *Int J Cancer* 2003; 105:14-9.
79. Liu B, Weinzimer SA, Beers-Gibson T, Mascarenhas D, Cohen P. Type I-alpha Collagen is an IGFBP-3 Binding Protein. *Growth Hormone & IGF Research* 2003; 13:89–97.
80. Ngo TH, Barnard RJ, Leung PS, Cohen P, Aronson WJ. Insulin-Like Growth Factor I (IGF-I) and IGF Binding Protein-1 Modulate Prostate Cancer Cell Growth and Apoptosis: Possible Mediators for the Effects of Diet and Exercise on Cancer Cell Survival. *Endocrinology* 2003; 144:2319-24.
81. Wetterau LA, Francis MJ, Ma L, Cohen P. Insulin-like growth factor I stimulates telomerase activity in prostate cancer cells. *J Clin Endocrinol Metab.* 2003; 88:3354-9.
82. Ngo TH, Barnard RJ, Cohen P, Freedland S, Tran C, DeGregorio F, Elshimali YI, Heber D, Aronson WJ. Effect of Isocaloric Low-fat Diet on Human LAPC-4 Prostate Cancer Xenografts in Severe Combined Immunodeficient Mice and the Insulin-like Growth Factor Axis. *Clin Cancer Res.* 2003; 9:2734-43.
83. Ikonen M, Liu B, Hashimoto Y, Ma L, Lee KW, Niikura T, Nishimoto I, Cohen P. Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis. *Proc Natl Acad Sci U S A.* 2003; 100:13042–13047.

84. Mikheev AM, Mikheeva SA, Liu B, Cohen P, Zarbl H. A functional genomics approach for the identification of putative tumor suppressor genes: Dickkopf-1 as suppressor of HeLa cell transformation. *Carcinogenesis*. 2004; 25:47-59.
85. Lee KW, Liu B, Ma L, Li H, Bang P, Koeffler HP, Cohen P. Cellular internalization of insulin-like growth factor binding protein-3 (IGFBP-3): Distinct endocytic pathways facilitate reuptake and nuclear localization. *J Biol Chem*. 2004; 279:469-76.
86. Licinio J, Caglayan S, Ozata M, Yildiz BO, De Miranda PB, O'Kirwan F, Whitby R, Liang L, Cohen P, Bhasin S, Krauss RM, Veldhuis JD, Wagner AJ, DePaoli AM, McCann SM, Wong ML. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. *Proc Natl Acad Sci U S A*. 2004; 101:4531-6.
87. Ikezoe T, Tanosaki S, Krug U, Liu B, Cohen P, Taguchi H, Koeffler HP. Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Antagonizes the Effects of Retinoids in Myeloid Leukemia Cells. *Blood*. 2004; 104:237-42.
88. Shim ML, Levitt Katz LE, Davis J, Dotzler WC, Cohen P, Ferry RJ Jr. Insulin-like growth factor binding protein-3 is a novel mediator of apoptosis in insulin-secreting cells. *Growth Horm IGF Res*. 2004; 14:216-25.
89. Shim ML, Moshang T Jr, Oppenheim WL, Cohen P. Is treatment with growth hormone effective in children with cerebral palsy? *Dev Med Child Neurol*. 2004; 46:569-71.
90. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. *Mol Cell Biol*. 2004; 24:7275-83.
91. Rosen CJ, Ackert-Bicknell C, Beamer WG, Nelson T, Adamo M, Cohen P, Bouxsein ML, Horowitz MC. Allelic differences in a quantitative trait locus affecting insulin-like growth factor-I impact skeletal acquisition and body composition. *Pediatr Nephrol*. 2005; 20:255-60.
92. Silha JV, Gui Y, Mishra S, Leckstrom A, Cohen P, Murphy LJ. Overexpression of Gly56/Gly80/Gly81-Mutant IGFBP-3 in Transgenic Mice. *Endocrinology*. 2005; 146:1523-31.
93. Grimberg A, Coleman CM, Burns TF, Himelstein BP, Koch CJ, Cohen P, El-Deiry WS. p53-dependent and p53-independent induction of IGFBP-3 by DNA damage and hypoxia. *J Clin Endocrinol Metab*. 2005; 90:3568-74.
94. Lee KW, Ma L, Yan X, Liu B, Zhang XK, Cohen P. Rapid apoptosis induction by IGFBP-3 involves an IGF -independent nucleo-mitochondrial translocation of RXRalpha/Nur77. *J Biol Chem*. 2005; 280:16942-8.
95. Ferry Jr RJ, Cohen P, Levitt Katz LE. Pharmacodynamic Considerations with Recombinant Human Insulin-Like Growth Factor-I in Children. *Horm Res*. 2005; 63:220-227
96. Liu B, Lee KW, Li H, Ma L, Lin GL, Chandraratna RA, Cohen P. Combination therapy of insulin-like growth factor binding protein-3 and retinoid X receptor ligands synergize on prostate cancer cell apoptosis in vitro and in vivo. *Clin Cancer Res*. 2005;11:4851-6.

97. Freedland SJ, Aronson WJ, Trock B, Cohen P, Kane CJ, Amling CL, Presti JC Jr, Terris MK; Shared Equal Access Regional Cancer Hospital Database Study Group. Racial differences in prognostic value of adult height for biochemical progression following radical prostatectomy. *Clin Cancer Res.* 2005 Nov 1;11(21):7735-42.
98. Oh SH, Kim WY, Kim JH, Younes MN, El-Naggar AK, Myers JN, Kies M, Cohen P, Khuri F, Hong WK, Lee HY. Identification of IGFBP-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma. *Clin Cancer Res.* 2006; 12:653-61.
99. Oufattole M, Lin SW, Liu B, Mascarenhas D, Cohen P, Rodgers BD. RNA polymerase II binding subunit 3 (Rpb3), a potential nuclear target of IGFBP-3. *Endocrinology.* 2006; 147:2138-46.
100. Benini S, Zuntini M, Manara MC, Cohen P, Nicoletti G, Nanni P, Oh Y, Picci P, Scotlandi K. Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma. *Int J Cancer.* 2006; 119:1039-1046.
101. Colon E, Strand ML, Carlsson-Skwirut C, Wahlgren A, Svechnikov KV, Cohen P, Soder O. Anti-apoptotic factor humanin is expressed in the testis and prevents cell-death in leydig cells during the first wave of spermatogenesis. *J Cell Physiol.* 2006; 208:373-85.
102. Yakar S, Bouxsein ML, Canalis E, Sun H, Glatt V, Gundberg C, Cohen P, Hwang D, Boisclair Y, Leroith D, Rosen CJ. The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. *J Endocrinol.* 2006; 189:289-99.
103. Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Cohen P, Leung P, Hong-Gonzalez J, Freedland SJ, Said J, Gui D, Seeram NP, Popoviciu LM, Bagga D, Heber D, Glaspy JA, Aronson WJ. Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. *Clin Cancer Res.* 2006; 12:4662-70.
104. Muzumdar RH, Ma X, Fishman S, Yang X, Atzmon G, Vuguin P, Einstein FH, Hwang D, Cohen P, Barzilai N. Central and Opposing Effects of IGF-I and IGF-Binding Protein-3 on Systemic Insulin Action. *Diabetes.* 2006; 55:2788-96.
105. Cobb LJ, Liu B, Lee KW, Cohen P. Phosphorylation by DNA-Dependent Protein Kinase Is Critical for Apoptosis Induction by Insulin-Like Growth Factor Binding Protein-3. *Cancer Res.* 2006; 66:10878-10884.
106. Ali O, Shim M, Fowler E, Greenberg MM, Perkins D, Oppenheim W, Cohen P. Growth Hormone Therapy Improves Bone Mineral Density in Children with Cerebral Palsy: A preliminary Pilot Study. *J Clin Endocrinol Metab.* 2007; 92(3):932-7.
107. Kim HS, Ali O, Shim M, Lee KW, Vuguin P, Muzumdar R, Barzilai N, Cohen P. Insulin-Like Growth Factor Binding Protein-3 Induces Insulin Resistance in Adipocytes In Vitro and in Rats In Vivo. *Pediatr Res.* 2007; 61:159-164. **Also included the art for the Journal Cover**

108. Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y, Shiri L, Pollak M, Lin S, Cohen P. IGFBP-3 inhibition of prostate cancer growth involves suppression of angiogenesis. *Oncogene*. 2007; 26:1811-9.
109. Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfeld RG; American Norditropin Study Group. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. *J Clin Endocrinol Metab*. 2007; 92:2480-6.
110. Lee KW, Cobb L, Ma L, Liu B, Milbrandt J, Cohen P. Contribution of the Orphan Nuclear Receptor Nur77 to the Apoptotic Action of IGFBP-3. *Carcinogenesis*. 2007; 28:1653-8.
111. Degraff DJ, Malik M, Chen Q, Miyako K, Rejto L, Aguiar AA, Bancroft DR, Cohen P, Sikes RA. Hormonal regulation of IGFBP-2 proteolysis is attenuated with progression to androgen insensitivity in the LNCaP progression model. *J Cell Physiol*. 2007; 213:261-8.
112. Ali O, Shim M, Fowler E, Cohen P, Oppenheim W. Spinal Bone Mineral Density, IGF-1 and IGFBP-3 in Children with Cerebral Palsy. *Horm Res*. 2007; 68:316-320
113. Barnard RJ, Leung PS, Aronson WJ, Cohen P, Golding LA. A mechanism to explain how regular exercise might reduce the risk for clinical prostate cancer. *Eur J Cancer Prev*. 2007; 16:415-21.
114. Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, Glodé LM, Greenberg NM, Hwang D, Cohen P, Pollak MN, Agarwal R. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. *Cancer Res*. 2007; 67:11083-91.
115. Hwang DL, Lee PD, Cohen P. Quantitative ontogeny of murine insulin-like growth factor (IGF)-I, IGF-binding protein-3 and the IGF-related acid-labile subunit. *Growth Horm IGF Res*. 2008; 18:65-74.
116. Freedland SJ, Mavropoulos J, Wang A, Darshan M, Demark-Wahnefried W, Aronson WJ, Cohen P, Hwang D, Peterson B, Fields T, Pizzo SV, and Isaacs WB. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. *Prostate*. 2008; 68:11-9
117. Suh Y, Atzmon G, Cho MO, Hwang D, Liu B, Leahy DJ, Barzilai N, Cohen P. Functionally significant insulin-like growth factor-I receptor mutations in centenarians. *PNAS*; 2008. 105:3438-42.
118. Ding F, Li HH, Zhang S, Solomon NM, Camper SA, Cohen P, Francke U. SnoRNA Snord116 (Pwcr1/MBII-85) Deletion Causes Growth Deficiency and Hyperphagia in Mice. *PLoS ONE*. 2008; 3:e1709.
119. Kobayashi N, Barnard RJ, Said J, Hong-Gonzalez J, Corman DM, Ku M, Doan NB, Gui D, Elashoff D, Cohen P, Aronson WJ. Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model. *Cancer Res*. 2008; 68:3066-73.

120. Torng PL, Lee YC, Huang CY, Ye JH, Lin YS, Chu YW, Huang SC, Cohen P, Wu CW, Lin CT. Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma. *Oncogene*. 2008; 27:2137-47.
121. Anzo M, Cobb LJ, Hwang DL, Mehta H, Said JW, Yakar S, LeRoith D, Cohen P. Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression. *Cancer Res*. 2008; 68:3342-9.
122. Jung Yoon Park JY, Cho MO, Leonard S, Calder B, Mian IS, Kim WH, Wijnhoven S, vanSteege H, Mitchell J, vanderHorst GT, Hoeijmakers J, Cohen P, Vijg J, Suh Y. Homeostatic Imbalance between Apoptosis and Cell Renewal in the Liver of Premature Aging XpdTTD Mice. *PLoS ONE*. 2008; 3:e2346.
123. Yakar S, Rosen CJ, Bouxsein ML, Sun H, Mejia W, Kawashima Y, Wu Y, Emerton K, Williams V, Jepsen K, Schaffler MB, Majeska RJ, Gavrilova O, Gutierrez M, Hwang D, Pennisi P, Frystyk J, Boisclair Y, Pintar J, Jasper H, Domene H, Cohen P, Clemmons D, Leroith D. Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. *FASEB J*. 2009; 23:709-19.
124. Miyako K, Cobb LJ, Francis M, Huang A, Peng B, Pintar JE, Ariga H, Cohen P. PAPA-1 Is a Nuclear Binding Partner of IGFBP-2 and Modulates Its Growth-Promoting Actions. *Mol Endocrinol*. 2009; 23:169-75.
125. Lenders CM et al on behalf of the Elizabeth Glaser Pediatric Research Network Obesity Study Group. Relation of body fat indexes to vitamin D status and deficiency among obese adolescents. *Am J Clin Nutr*. 2009; 90:459-67.
126. Mavropoulos JC, Buschemeyer WC 3rd, Tewari AK, Rokhfeld D, Pollak M, Zhao Y, Febbo PG, Cohen P, Hwang D, Devi G, Demark-Wahnefried W, Westman EC, Peterson BL, Pizzo SV, Freedland SJ. The Effects of Varying Dietary Carbohydrate and Fat Content on Survival in a Murine LNCaP Prostate Cancer Xenograft Model. *Cancer Prev Res*. 2009; 6:557-65.
127. Lenders CM, Feldman HA, Von Scheven E, Merewood A, Sweeney C, Wilson DM, Lee PD, Abrams SH, Gitelman SE, Wertz MS, Klish WJ, Taylor GA, Chen TC, Holick MF; on behalf of the Elizabeth Glaser Pediatric Research Network Obesity Study Group. Relation of body fat indexes to vitamin D status and deficiency among obese adolescents. *Am J Clin Nutr*. 2009; 90:459-67.
128. Fan Y, Menon RK, Cohen P, Hwang D, Clemens T, Digirolamo DJ, Kopchick JJ, Leroith D, Trucco M, Sperling MA. Liver-specific Deletion of the Growth Hormone Receptor Reveals Essential Role of GH Signaling in Hepatic Lipid Metabolism. *J Biol Chem*. 2009 May 21. [Epub ahead of print]
129. Cobb LJ, Mehta H, Cohen P. Enhancing the Apoptotic Potential of Insulin-like Growth Factor-Binding Protein-3 in Prostate Cancer by modulation of CK2 Phosphorylation. *Mol Endocrinol*. 2009 Jun 25. [Epub ahead of print]
130. Muzumdar RH, Huffman DM, Atzmon G, Buettner C, Budagov T, Cui L, Einstein FH, Cobb LJ, Fishman S, Poduval A, Hwang D, Barzilai N, Cohen P. Humanin: A Novel Regulator of Peripheral Insulin Action. *PLoS ONE*. 2009; 4(7): e6334.
131. Glaser Pediatric Research Network Obesity Study Group. Intra-peritoneal Fat and Insulin Resistance in Obese Adolescents. *Obesity (Silver Spring)*. Epub 2009 Aug 27.

132. Hoang PT, Park P, Cobb LJ, Paharkova-Vatchkova V, Hakimi M, Cohen P, Lee KW. The neurosurvival factor Humanin inhibits beta-cell apoptosis via signal transducer and activator of transcription 3 activation and delays and ameliorates diabetes in nonobese diabetic mice. *Metabolism*. 2009 Sep 30. [Epub ahead of print]
133. Aronson WJ, Barnard RJ, Freedland SJ, Henning S, Elashoff D, Jardack PM, Cohen P, Heber D, Kobayashi N. Growth Inhibitory Effect of a Low-fat Diet on Prostate Cancer Cells: Results of a Prospective Randomized Dietary Intervention Trial in Men with Prostate Cancer. *Journal of Urology*. 2009; In Press.
134. Koyama S, Cobb LJ, Mehta H, Seeram NP, Heber D, Pantuck AJ, Cohen P. Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis. *Growth Horm IGF Res*. 2009; In Press.

Editorials and Reviews

135. Cohen P, Fielder PJ, Hasegawa Y, Frisch H, Giudice LC, Rosenfeld RG: Clinical aspects of insulin-like growth factor binding proteins. *Acta Endocrinol* [Copenh] 124[Suppl 2]:74-85, 1991.
136. Neely EK, Beukers WM, Oh Y, Cohen P, Rosenfeld RG: Insulin-like growth factor receptors. *Acta Paediatr Scand* [Suppl] 372:116-21, 1991.
137. Fielder PJ, Guevara-Aguirre J, Rosenbloom AL, Cohen P, Hintz RL, Rosenfeld RG: Regulation of serum insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) in Ecuadorian growth hormone receptor deficient patients. *Acta Paediatr Scand* [Suppl] 377:104-109, 1991.
138. Cohen P, Ocran I, Fielder PJ, Neely EK, Lamson G, Oh Y, Deal LC, Pham H, Gargosky SE, Giudice Rosenfeld RG: Insulin-like growth factors: Implications for aging. *Psyconeuroendocrinology*, 1992.
139. Lamson G, Giudice LC, Cohen P, Fielder PJ, Oh Y, Hintz RL, Rosenfeld RG: Proteolysis of insulin-like growth factor binding protein-3 may be a common regulatory mechanism of IGF action in vivo. *Growth Regulation*, 3:91-95, 1993.
140. Rosenbloom AL, Guevara-Aguirre J, Fielder PJ, Gargosky SE, Cohen P, Rosenfeld RG. Insulin-like growth factor binding proteins -2 and -3 in Ecuadorian patients with growth hormone receptor deficiency and their parents. In: Lessons from Laron Syndrome, *Pediatric and Adolescent Endocrinology*, Basel, Karger Vol 24, p 185-191, 1993.
141. Fielder PJ, Gargosky SE, Wilson K, Vaccarello M, Cohen P, Diamond F, Guevara-Aguirre J, Rosenbloom AL, Rosenfeld RG: Serum Profiles of IGFs and IGFBPs in Adults with Growth Hormone Insensitivity Syndrome (GHIS) Treated with IGF-I. *Acta Paediatr Scand* [Suppl], 82:40-43, 1993.
142. Cohen P, Lamson G, Okajima T, Rosenfeld RG: Transfection of the human IGFBP genes into Balb/c fibroblasts: a model for the cellular functions of IGFBPs. *Growth Regulation*, 3:23-26, 1993.
143. Rosenfeld RG, H. Pham, Cohen P et. al.: Physiology of the Insulin-like growth factor binding proteins. *Acta. Paediatrica* (Suppl). 399:154-8, 1994.
144. Cohen P, Peehl DM, Rosenfeld RG: The insulin-like growth factor axis in the Prostate. *Horm Metab Res*, 26:81-4; 1994.
145. Cohen P, Rosenfeld RG: Physiological and Clinical Relevance of the IGFBPs. *Current Opinions in Pediatrics*. 1994. 6:462-467.
146. Katz LEL, Rosenfeld RG, Cohen P: Clinical Significance of IGFBPs. *The Endocrinologist*. 5: 41-8; 1995.
147. Peehl DM, Cohen P, Rosenfeld RG: The IGF system in the prostate. *World Journal of Urology*. 13:306-311, 1995.
148. Rajah R, Katz L, Nunn S, Solberg P, Beers T, and Cohen P. IGFBP proteases - functional regulators of cell growth. *Progress in Growth Factors Research*, 6:273-284, 1996.

149. Peehl DM, Cohen P, Rosenfeld RG: The role of insulin-like growth factors in prostate biology. *J. Andrology*, 17:2-4, 1996.
150. Solberg P, Cohen P: The role of the insulin-like growth factor binding proteins and their proteases in modulating IGF action. In: *Endocrinology and Metabolism Clinics of North America*, 25:591-614, 1996.
151. Nunn SE, Beers-Gibson T, Cohen P. Regulation of prostate cell growth by the IGFbps and their proteases. *Endocrine* 7:115-118;1997.
152. Grimberg A, Cohen P: Optimizing Growth Hormone therapy in children. *Hormone Research* 1997; 58 (suppl 5):11-15.
153. Cohen P, Peehl DM, Rosenfeld R. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. *Br J Cancer* 1998; 78:554-556.
154. Cohen P. Implications of IGF-I elevations in prostate cancer sera. *Journal of the National Cancer Institute*. 1998 Jun 17;90(12):876-879.
155. Ferry RJ Jr, Katz LE, Grimberg A, Cohen P, Weinzimer SA. Cellular actions of insulin-like growth factor binding proteins. *Horm Metab Res* 1999; 31:192-202.
156. Grimberg A, Cohen P: Growth hormone and prostate cancer: Guilty by association? 22:64-73, 1999 *J Endocrinol Invest*.
157. Ferry Jr RJ, Cohen P. The Insulin-Like Growth Factor Axis in Pediatrics. *Clin Pediatr Endocrinol*. 1999; 8:1-10.
158. Wetterau LA, Moore MG, Lee KW, Shim ML, Cohen P. Novel Aspects of the Insulin-like Growth Factor Binding Proteins. *Mol Genet Metab* 1999; 68:161-181.
159. Shim M, Cohen P. IGFs and human cancer: implications regarding the risk of growth hormone therapy. *Horm Res* 1999;51 Suppl 3:42-51
160. Burren CP, Wanek D, Mohan S, Cohen P, Guevara-Aguirre J, Rosenfeld RG. Regulation of serum IGFBP-4, IGFBP-5 and ALS by GH but not IGF-I. *Acta. Paediatrica* 1999; 428[S1]:185-191.
161. Grimberg A, Cohen P: Role of insulin-like growth factors in growth control and carcinogenesis. *J Cell Physiol* 2000;183:1-9.
162. Officers of the GH Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. *J Clin Endocrinol Metab* 2000; 85:3990-3.
163. Pollak M, Besser GM, Cohen P Rosenfeld RG. Growth Hormone, IGFs and Neoplasia – An Overview. *Growth Hormone and IGF Research* 10:S1-3; 2000
164. Collett-Solberg PF, Cohen P. Genetics, chemistry, and function of the IGF/IGFBP system. *Endocrine* 2000; 12:121-36.
165. Wetterau L, Cohen P. New Paradigms for GH Therapy in Children. *Horm Res* 2000; 53: S3 31-36.

166. Clayton PE, Cohen P, Tanaka T, Hintz RL, Laron Z, Sizonenko PC. Diagnosis of Growth Hormone Deficiency in Childhood. *Horm Res* 2000; 53: Suppl S3 30.
167. Cohen P, DR Clemmons RG Rosenfeld. Does the GH –IGF axis play a role in cancer pathogenesis? *Growth Hormone & IGF Research* 2000, 10:1–9.
168. Wetterau L, Cohen P. Role of insulin-like growth factor monitoring in optimizing growth hormone therapy. *J Pediatr Endocrinol Metab* 2000;13 Suppl 6:1371-6.
169. Cohen P, Franklin S, Rogol A, Bright G, Rosenfeld RG, on behalf of the North American Norditropin Study Group. What is the optimal dose of growth hormone? Medical Forum Highlights. 2000; 1:4-5.
170. Officers of the GH Research Society. Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. *J Clin Endocrinol Metab* 2001; 86:1868-70.
171. Sizonenko PC, Clayton PE, Cohen P, Hintz RL, Tanaka T, Laron Z. Diagnosis and management of growth hormone deficiency in childhood and adolescence. Part 1: Diagnosis of growth hormone deficiency. *Growth Hormone and IGF Research*, 11: 137-165, 2001.
172. Lee K, Cohen P. Individualizing Growth Hormone Dosing in Children. *Horm Res* 2001; 56 (suppl 1): 29–34.
173. Cohen P. Clinical implications of the IGF-cancer connection. *Growth Horm IGF Res* 2001; 11:336-8.
174. H Simpson, R Savine, P Sonksen BA Bengtsson, L Carlsson, JS Christiansen, D Clemmons, P Cohen. R Hintz, K Ho, P Mullis, I Robinson, C Strasburger, T Tanaka, M Thorner. Growth hormone replacement therapy for adults: Into the new millennium. *Growth Hormone & IGF Research* 2002, 12, 1–33.
175. Tanaka T, Cohen P, E Clayton P, Laron Z, L Hintz R, C Sizonenko P. Diagnosis and management of growth hormone deficiency in childhood and adolescence - Part 2: Growth hormone treatment in growth hormone deficient children. *Growth Horm IGF Res* 2002; 12:323-9.
176. Lee KW, Cohen P. Nuclear effects: unexpected intracellular actions of insulin-like growth factor binding protein-3. *J Endocrinol* 2002; 175:33-40.
177. Monzavi R, Cohen P. IGFs and IGFFBPs: role in health and disease. *Best Pract Res Clin Endocrinol Metab.* 2002; 16:433-47.
178. Sperling MA, Saenger PH, Ray Hintz, Tom Wilson, Rose SR, on behalf of the LWPES drug and therapeutic committee. Growth hormone treatment and neoplasia-coincidence or consequence? *J Clin Endocrinol Metab* 2002; 87:5351-2
179. Lee K-W, Cohen P. Individualized Growth Hormone Therapy in Children: Advances Beyond Weight-based Dosing. 2003 *J Ped Endo Metab* 16:625-630.
180. Wilson TA, Rose SR, Cohen P, Rogol AD, Backeljauw P, Brown R, Hardin DS, Kemp SF, Lawson M, Radovick S, Rosenthal SM, Silverman L, Speiser P. Update of guidelines for the use of growth hormone in children: The Lawson Wilkins pediatric endocrinology society drug and therapeutics committee. *J Pediatr.* 2003; 143:415-21.

181. Ali O, Cohen P. Insulin-like growth factors and their binding proteins in children born small for gestational age: implication for growth hormone therapy. *Horm Res.* 2003; 60:S115-23.
182. Ali O, Cohen P, Lee KW. Epidemiology and Biology of Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) as an Anti-cancer Molecule. *Horm Metab Res.* 2003; 35:726-33.
183. Denny CT, Cohen P. Pancreatic Beta Cells - The Sweet Life. *Pediatr Res.* 2004; 55:361-2.
184. Cohen P, Dunger DB. Hot topics. *Growth Horm IGF Res.* 2004; 14:S34.
185. Park P, Cohen P. The role of insulin-like growth factor I monitoring in growth hormone-treated children. *Horm Res.* 2004; 62: S59-65.
186. Randhawa R, Cohen P. The role of the insulin-like growth factor system in prenatal growth. *Mol Genet Metab* 2005; 86:84-90.
187. Yang J, Anzo M, Cohen P. Control of aging and longevity by IGF-I signaling. *Exp Gerontol.* 2005; 40:867-72.
188. Park P, Cohen P. Insulin-like growth factor I (IGF-I) measurements in growth hormone (GH) therapy of idiopathic short stature (ISS). *Growth Horm IGF Res.* 2005;15:S13-20.
189. Cohen P. Overview of the IGF-I system. *Horm Res* 2006; 65 Supp 1:3-8.
190. Cohen P. Insulin-Like Growth Factor Binding Protein-3: Insulin-Like Growth Factor Independence Comes of Age. *Endocrinology.* 2006; 147:2109-2111.
191. Pawlikowska-Haddad A, Cohen P. Advances in pediatric growth hormone therapy: IGF-I-based dosing. *Indian Pediatr.* 2006; 43:577-81.
192. Cohen P. Controversy in Clinical Endocrinology: Problems with Reclassification of IGF-1 Production and Action Disorders. *J Clin Endocrinol Metab.* 2006; 91:4235-6.
193. Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A, et al. Management of the Child Born Small for Gestational Age Child (SGA) through to Adulthood: A Consensus Statement of the International Societies of Paediatric Endocrinology and the Growth Hormone Research Society. *J Clin Endocrinol Metab.* 2007; 92:804-10.
194. Rosenthal S, Cohen P, Clayton P, Backeljauw P, Bang P, Ten S. Treatment perspectives in idiopathic short stature with a focus on IGF-I deficiency. *Pediatr Endocrinol Rev.* 2007 May;4 Suppl 2:252-71.
195. Kaplan SA, Cohen P. The Somatomedin Hypothesis 2007: Fifty Years Later. *J Clin Endocrinol Metab.* 2007; 92:4529-35.
196. Ho KK et al. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society and Endocrine Society of Australia. *Eur J Endocrinol.* 2007; 157: 695—700.

197. Wit JM, Clayton PE, Rogol AD, Savage MO, Saenger PH, Cohen P. Idiopathic short stature: Definition, epidemiology, and diagnostic evaluation. *Growth Horm IGF Res.* 2008; 18:89-110.
198. Wit JM, Reiter EO, Ross JL, Saenger PH, Savage MO, Rogol AD, Cohen P. Idiopathic short stature: Management and growth hormone treatment. *Growth Horm IGF Res.* 2008; 18:111-35.
199. Cohen P. Serum insulin-like growth factor I (IGF-I) level should be part of the evaluation of children with short stature. *Pediatr Endocrinol Rev.* 2008; 5 Suppl 3:834-6.
200. Salusky IB, Cohen P. Lost in translation? *Pediatr Res.* 2008; 64:225.
201. P Cohen, AD Rogol, CL Deal, P Saenger, EO Reiter, JL Ross, SD Chernausek, M0 Savage, JM Wit on behalf of the 2007 ISS Consensus Workshop participants. Consensus Guidelines for the Diagnosis and Treatment of Children with Idiopathic Short Stature: A Summary Statement of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. *J Clin Endocrinol Metab* 93: 4210–4217, 2008.
202. Hernandez MI, Cohen P. Surprising New Height Regulating Genes: Beyond Growth Hormone and IGF-I. *Pediatr Res.* 2008; 64:461.
203. Cohen P. Growth hormone treatment: evidence, practice, and emerging issues. *Manag Care.* 2009; 18(8 Suppl 6):2-3.
204. Keni J, Cohen P. Optimizing growth hormone dosing in children with idiopathic short stature. *Horm Res.* 2009; 71 Suppl 1:70-4.
205. Cohen P. Clinical management of growth hormone therapy for children. *Manag Care.* 2009; 18(8 Suppl 6):4-9.

Chapters in Textbooks and Proceedings

1. Cohen P, Rosenfeld RG: Growth problems in adolescence. In: *Textbook of Adolescent Medicine*, Editors: MacAnarney, Kreipe, Orr, and Comerci. p.p. 494-508. WB Saunders, Philadelphia, 1992.
2. Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J, Berg MA, Cohen P, et al.: Laron-type dwarfism in Ecuador. In: *Proceedings of the 9th International Congress of Endocrinology*, 1993, p 85-9.
3. Cohen P, Fielder PJ, Guevara-Aguirre J, Diamond FB, Wilson K, Berg MA, Francke U, Gargosky SE, Vaccarello MA, Rosenbloom AL, Rosenfeld RG. Medical and scientific aspects of growth hormone receptor deficiency (Laron syndrome) in Ecuador. In: *Growth hormone II: basic and scientific aspects*, Editor: B. Bercu. Serono Symposia, page 279-285, 1994.
4. Cohen P, Peehl DM, Bhalra A, Dong G, Hintz RL, Rosenfeld RG: The IGF axis in prostatic disease. In: *The IGFs and their regulatory proteins*. R.C. Baxter, P.D. Gluckman, R.G. Rosenfeld, editors. Elsevier Science B.V. Amsterdam. p.p. 369-77. 1994.
5. Cohen P, Rosenfeld RG: The insulin-like growth factor axis. In: *Human Growth Hormone, Basic and Scientific Aspects*, Editor: Rosenbloom AL, Shiverick J. CRC Press, Boca Raton, Florida, pp: 43-58. 1995.
6. Cohen P, Rosenfeld RG: Growth regulation. In: *Textbook of Endocrine Physiology*, Editors: Griffin and Ojeda. Oxford University Press pages 244-259; 1996.
7. Katz LEL, Cohen P: Growth factors in the fetus. *Textbook of neonatal physiology*. WB Saunders, Philadelphia, pp 268-279, Editor, Pollin R, 1997.
8. Grimberg A, Rajah R, Zhao H, Cohen P: The prostatic IGF system: new levels of complexity. In: *Molecular mechanisms to regulate the Activities of Insulin-like Growth factors*, Takano, Hizuka, and Takahashi, eds. pp 205-215, 1998.
9. Weinzimer S, Cohen P: The IGF axis in the male reproductive system, In: *The IGFs*, Rosenfeld and Roberts, ed, 1999 p.p. 172-184.
10. Collett-Solberg PF, Rajah R, Weinzimer SA, Cohen P. The impact of IGFBPs and IGFBP proteases on tissue growth. In: Johnston FE, Eveleth PB, Zemel B (ed). *Human Growth in Context*. London: Smith-Gordon, 1999.
11. Cohen P: Hyperpituitarism, Tall Stature, and Overgrowth Syndromes. In: *Nelson Textbook of Pediatrics*, 16th edition, Behrman, Kliegman. Jenson, Barlow, eds. W. B. Saunders, 1999.
12. Cohen P, Rosenfeld RG: Growth regulation. In: *Textbook of Endocrine Physiology*, 2nd edition, Editors: Griffin and Ojeda. Oxford University Press; 2001.
13. Cohen P, Rosenfeld RG: Growth Disorders. In: *Textbook of Pediatric Endocrinology*, 2nd edition, Editor: Sperling M. 2002.
14. Weinzimer S, Cohen P. Biological significance of the IGFBPs. *Growth and Lactogenic Hormones*. R Rappaport Ed. Elsevier Science B.V. 2002.

15. Cohen P, Ballard P: Mechanisms of Hormone Action. In: *Rudolph Textbook of Pediatrics*, 4th edition, 2003.
16. Cohen P: Hyperpituitarism, Tall Stature, and Overgrowth Syndromes. In: *Nelson Textbook of Pediatrics*, 17th edition, Behrman, Kliegman, Jenson, Barlow, Eds. W. B. Saunders, 2003.
17. De Leon D, Cohen P, Katz LEL: Growth factors and the regulation of fetal growth. *Textbook of neonatal physiology*. WB Saunders, Philadelphia, pp 1880-1890, Editors, Polin, Fox, Abman, 2004.
18. Cohen P, Rosenfeld RG: Growth regulation. In: *Textbook of Endocrine Physiology*, 3rd edition, Editors: Griffin and Ojeda. Oxford University Press; 2004.
19. Heber D and Cohen P. Endocrine and paracrine factors in carcinogenesis. In *Nutritional Oncology*. 2nd Edition. Editors: Heber, Blackburn, Go and Milner. Academic Press 2006.
20. Cohen P: Hyperpituitarism, Tall Stature, and Overgrowth Syndromes. In: *Nelson Textbook of Pediatrics*, 18th edition, Behrman, Kliegman, Jenson, Barlow, Eds. W. B. Saunders, 2007.
21. Cohen P, Rosenfeld RG: Growth Disorders. In: *Textbook of Pediatric Endocrinology*, 3rd edition, Editor: Sperling M. 2008.
22. Ali O, Cohen P. The Pituitary Gland and Growth Failure. In: *Manual of Endocrinology* 4th edition, Lippincott, Wilkins, Williams Editor: Lavin N. 2009.
23. Hosono E, Cohen P: Hyperpituitarism, Tall Stature, and Overgrowth Syndromes. In: *Nelson Textbook of Pediatrics*, 18th edition, Behrman, Kliegman, Jenson, Barlow, Eds. W. B. Saunders, 2009.

Internet publications:

1. Ferry RF, Cohen P. Beckwith-Wiedemann Syndrome. 2001 www.Emedicine.com
2. Wetterau L, Cohen P. Laron Syndrome. 2002 www.Emedicine.com
3. Shim M, Cohen P. Gigantism and Acromegaly. 2002 www.Emedicine.com
4. Wetterau L, Cohen P. Hypopituitarism. 2002 www.Emedicine.com
5. Shim M, Cohen P. Hyperpituitarism. 2003 www.Emedicine.com
6. P. Cohen. GH treatment of SGA. In: *A team approach to the management of SGA*. WB Zipf, Editor. CMA Network series on the web 2004. www.cmanetwork.com
7. P. Cohen. New Areas of Growth: Diagnosis and Treatment of IGF-1 Deficiency". Rosenfeld RG, Editor. 2006. CME series at www.IGFDforum.com
8. C Alter, N Mauras, P Cohen. Growth Hormone for ISS. Endocrine News. Endocrine Society Tri-point Series October 2006. www.ENDO-SOC.ORG
9. P. Cohen. Understanding IGF Deficiency. IGFD Forum. July 2007. <http://igfdforum.com>.
10. P. Cohen: ISS Workshop: Guidelines for diagnosis and therapy. 2008. <http://igfdforum.com>.
11. Rosenfeld RG, Sperling MA, Cohen P, Allen DB, Nelly Mauras N. Growth and Growth Hormone: Current Applications and Clinical Updates. 2008. <http://www.endocrinetoday.com/view.aspx?rid=42146&bypass=true>

Editor for Books, Proceedings and Medical Websites:

1. Ritzin M, Lippe B, Chernicov P, Cohen P (eds). Proceedings of the 28th International Workshop on Growth Hormone. Horm Res 2000; 53:S3.
2. Pollak M, Besser GM, Cohen P, Rosenfeld RG (eds). Proceedings of the First International Workshop on Growth Hormone, IGFs and Neoplasia. Growth Hormone and IGF Research 10: Supplement A; 2000.
3. Cohen P (editor). Diabetes in Children. Yourdoctor.com. 2001
4. Cohen P (editor). Interpretation of Endocrine Laboratory Tests. SpecialtyLaboratories.com. 2002
5. Cohen P (guest editor). Medical Forum Highlights. GH Treatment of ISS. 2008.
6. Cohen P. Growth hormone treatment: evidence, practice, and emerging issues. Manag Care. 2009; 18(8 Suppl 6):2-18.